HomeCompareLLY vs CFG

LLY vs CFG: Dividend Comparison 2026

LLY yields 0.70% · CFG yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LLY wins by $1.51M in total portfolio value· pulled ahead in Year 4
10 years
LLY
LLY
● Live price
0.70%
Share price
$886.67
Annual div
$6.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.54M
Annual income
$1,207,534.19
Full LLY calculator →
CFG
CFG
● Live price
3.06%
Share price
$57.45
Annual div
$1.76
5Y div CAGR
14.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.4K
Annual income
$1,688.32
Full CFG calculator →

Portfolio growth — LLY vs CFG

📍 LLY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLLYCFG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LLY + CFG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LLY pays
CFG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LLY
Annual income on $10K today (after 15% tax)
$59.72/yr
After 10yr DRIP, annual income (after tax)
$1,026,404.06/yr
CFG
Annual income on $10K today (after 15% tax)
$260.40/yr
After 10yr DRIP, annual income (after tax)
$1,435.07/yr
At 15% tax rate, LLY beats the other by $1,024,968.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LLY + CFG for your $10,000?

LLY: 50%CFG: 50%
100% CFG50/50100% LLY
Portfolio after 10yr
$784.1K
Annual income
$604,611.26/yr
Blended yield
77.11%
📊

Analyst Conviction Gap

Where Wall Street is split right now

LLY
Analyst Ratings
33
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$1,243.95
+40.3% upside vs current
Range: $985.00 — $1,350.00
Altman Z
7.7
Piotroski
6/9
CFG
Analyst Ratings
31
Buy
6
Hold
1
Sell
Consensus: Buy
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LLY buys
10
CFG buys
12
PoliticianChamberTickerTypeAmountDate
David Taylor🏢 House$LLY▲ Buy$1,001 - $15,0002026-02-26
Angus King🏛 Senate$LLY▼ Sell$1,001 - $15,0002026-02-13
David Taylor🏢 House$LLY▼ Sell$1,001 - $15,0002026-02-09
David Taylor🏢 House$LLY▼ Sell$1,001 - $15,0002026-01-16
Angus King🏛 Senate$LLY▲ Buy$1,001 - $15,0002025-12-29
Angus King🏛 Senate$LLY▲ Buy$1,001 - $15,0002025-12-29
Markwayne Mullin🏛 Senate$LLY▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$LLY▲ Buy$15,001 - $50,0002025-12-29
Julie Johnson🏢 House$LLY▼ Sell$1,001 - $15,0002025-12-18
David Taylor🏢 House$LLY▼ Sell$1,001 - $15,0002025-12-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLLYCFG
Forward yield0.70%3.06%
Annual dividend / share$6.23$1.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%14.2%
Portfolio after 10y$1.54M$30.4K
Annual income after 10y$1,207,534.19$1,688.32
Total dividends collected$1.49M$8.6K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusBuyBuy

Year-by-year: LLY vs CFG ($10,000, DRIP)

YearLLY PortfolioLLY Income/yrCFG PortfolioCFG Income/yrGap
1$10,841$140.53$11,050$349.86$209.00CFG
2$11,884$284.74$12,236$412.60$352.00CFG
3$13,299$583.47$13,580$487.63$281.00CFG
4← crossover$15,451$1,220.47$15,108$577.61+$343.00LLY
5$19,183$2,650.30$16,852$685.86+$2.3KLLY
6$26,676$6,150.32$18,848$816.48+$7.8KLLY
7$44,530$15,986.45$21,142$974.64+$23.4KLLY
8$97,527$49,880.25$23,789$1,166.83+$73.7KLLY
9$308,551$204,197.51$26,855$1,401.25+$281.7KLLY
10$1,537,684$1,207,534.19$30,423$1,688.32+$1.51MLLY

LLY vs CFG: Complete Analysis 2026

LLYHealthcare

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Full LLY Calculator →

CFGFinancials

Citizens Financial Group, Inc. operates as the bank holding company for Citizens Bank, National Association that provides retail and commercial banking products and services to individuals, small businesses, middle-market companies, corporations, and institutions in the United States. The company operates in two segments, Consumer Banking and Commercial Banking. The Consumer Banking segment offers deposit products, mortgage and home equity lending products, credit cards, business loans, wealth management, and investment services; and auto, education, and point-of-sale finance loans, as well as digital deposit products. This segment serves its customers through telephone service centers, as well as through its online and mobile platforms. The Commercial Banking segment provides various financial products and solutions, including lending and leasing, deposit and treasury management services, foreign exchange, and interest rate and commodity risk management solutions, as well as syndicated loans, corporate finance, mergers and acquisitions, and debt and equity capital markets services. This segment serves government banking, not-for-profit, healthcare, technology, professionals, oil and gas, asset finance, franchise finance, asset-based lending, commercial real estate, private equity, and sponsor finance industries. It operates approximately 1,200 branches in 14 states and the District of Columbia; 114 retail and commercial non-branch offices in national markets; and approximately 3,300 automated teller machines. The company was formerly known as RBS Citizens Financial Group, Inc. and changed its name to Citizens Financial Group, Inc. in April 2014. Citizens Financial Group, Inc. was founded in 1828 and is headquartered in Providence, Rhode Island.

Full CFG Calculator →
📬

Get this LLY vs CFG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LLY vs SCHDLLY vs JEPILLY vs OLLY vs KOLLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.